Rocket Fuel
Prescribing
Information
Instructions
for Use
Important Safety
Information
Amgen
MedInfo
Prescribing Information Instructions for Use Important Safety Information Amgen MedInfo Live Assistance For Patients

Access for your patients

Neulasta® patients who need financial assistance for the Neulasta® Delivery Kit or prefilled syringe may be eligible for support from several sources. These include:

  • Independent co-pay foundations
  • The Safety Net Foundation, which provides Neulasta® at no cost for eligible patients
  • The Neulasta FIRST STEP® Co-Pay Coupon Program

Learn more about the Neulasta® Delivery Kit.

89% of Neulasta® patients had $0 out-of-pocket costs, based on a national claims database*1

*National claims database included 166,581 patients, across all insurance types, between January 2011 and August 2014.

Your patients may be eligible for the Neulasta® Co-Pay Coupon Program

The Neulasta FIRST STEP® Program is a co-pay coupon program to help commercially insured eligible patients with their deductible, co-insurance, and/or co-pay requirements for Neulasta® (pegfilgrastim).

Access coding and billing information for Neulasta.

Download the formulary fact sheet for Neulasta (includes On-body Injector and prefilled syringe).

Enrolling your practice

To enroll your practice in the Amgen FIRST STEP® Program, please call 1-888-65-STEP1 (1-888-657-8371). Offices must complete this process once prior to processing the Amgen FIRST STEP® Program Cards.

  Next:

Learn about assistance for uninsured patients

Reference:

  1. Data on file, Amgen.
Indication and Important Safety Information
SEE MORE

Indication

Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.